Quince Therapeutics (IRLA) Financials

Quince Therapeutics (NASDAQ:QNCX) remains a pre-revenue biotechnology company with no reported revenue throughout the periods provided. Its financial profile is therefore driven primarily by research spending, clinical development costs, financing activity and changes in its cash reserves rather than by operating sales.

Liquidity improved sharply in the second quarter of 2026. Cash and equivalents increased from $18.2 million at March 31, 2026, to $116.0 million at June 30, 2026. The company reported $108.9 million of financing cash inflow during the quarter, although only $5.4 million was specifically identified as common-equity issuance. Q2 operating cash burn was $18.9 million, compared with $7.6 million in Q1 2026 and approximately $10.5 million in Q4 2025. At the latest reported cash balance, QNCX has a substantially stronger near-term liquidity position, although its cash is dependent on continued access to capital markets.

The income statement continues to show substantial volatility. QNCX reported a $75.5 million net loss in Q2 2026 after recording a $35.9 million net profit in Q1. The first-quarter profit was largely supported by $45.2 million of other income, rather than recurring product revenue. Q2 research and development expense rose to $64.5 million from $6.8 million in Q1, while selling, general and administrative expense increased to $16.6 million from $4.3 million. A large portion of Q2’s $64.6 million of noncash adjustments appears to have reduced the difference between its accounting loss and operating cash burn.

The balance sheet is mixed. The company had $123.4 million of current assets and $8.5 million of current liabilities at June 30, 2026, indicating substantial short-term coverage. It also reported no short-term debt and no long-term debt in the provided Q2 balance sheet. However, total common equity was negative $35.3 million, compared with positive equity of $15.7 million in Q1, reflecting the latest quarter’s sizable loss and a $143.8 million redeemable noncontrolling interest classification.

• Cash reserves increased to $116.0 million at the end of Q2 2026 from $18.2 million in Q1, materially improving near-term financial flexibility.
• Current liquidity is strong: current assets of $123.4 million substantially exceeded current liabilities of $8.5 million, and the company reported no short-term debt.
• Financing activity provided $108.9 million of cash in Q2 2026, replenishing resources after several years of operating losses and cash consumption.
• Operating cash burn remains below the latest cash balance. Q2 operating outflow was $18.9 million, suggesting a potentially meaningful funding period if spending remains stable, although clinical costs can change rapidly.
• Research and development spending is highly volatile. Q2 R&D expense of $64.5 million was far above the $6.8 million reported in Q1, which may reflect increased development activity but makes future cash needs difficult to forecast.
• Q1 2026’s reported profit was not recurring operating profit. The $35.9 million net income was supported by $45.2 million of other income, while revenue remained zero.
• Investment activity has frequently affected cash flow. The company has repeatedly purchased, sold or matured investments, making changes in cash balances less indicative of underlying operating performance.
• QNCX has reported no revenue in the provided quarterly income statements, leaving the company dependent on financing and potential future commercialization or licensing proceeds.
• Net losses and operating cash outflows have persisted for years. Q2 2026’s $75.5 million net loss and $18.9 million operating cash burn followed losses of $39.5 million in Q4 2025 and $13.4 million in Q3 2025.
• Shareholder dilution remains a material risk. The company has used equity financing, and the reported share counts vary substantially across periods, including apparent effects from corporate actions and restatements. Additional capital raises could reduce existing shareholders’ ownership percentage.